To The Moon

Tonix Pharmaceuticals: Expects to Have Sufficient Cash to Fund Planned Operations Beyond FDA Pdufa G

$JNJ 20250417 175.0 CALL$

Palantir saw a pullback early in today's trading in conjunction with CEO Alex Karp's plan to sell $1.2 billion in company stock.Palantir stock saw big sell-offs in Wednesday's trading. The software specialist's share price ended the daily session down 10.1% and had been off as much as 12.9% earlier in trading.Palantir stock saw a pullback early in today's trading following a disclosure yesterday that CEO Alex Karp plans to sell $1.2 billion in company stock. Sell-offs intensified late in the day's trading following a report from The Washington Post that suggested big defense spending cuts could be on the horizon. According to the report, Defense Secretary Pete Hegseth has instructed Pentagon officials to prepare for budget cuts that could come in as high as 8% annually over the next five years. With Karp laying the groundwork to move forward with a new stock-selling plan and the potential for Palantir to see weaker public-sector demand, investors got multiple bearish signals today. Bu

Company had $98.8 million in cash as of December 31, 2024; existing cash expected to fund planned operations into the first quarter of 2026. Company is debt-free after repaying mortgage on facilities. TNX-102 SL fibromyalgia FDA PDUFA goal date is August 15, 2025. $10.1 million in net sales from migraine products in 2024. CHATHAM, N.J., Feb. 07, 2025 -- Tonix Pharmaceuticals Holding Corp. , a fully-integrated biopharmaceutical company with marketed products and a pipeline of development candidates, recently announced selected preliminary operating results for the year ended December 31, 2024, and certain preliminary financial condition information as of December 31, 2024. The above information is preliminary financial information for the year ended December 31, 2024 and subject to completion. The unaudited, estimated results for the year ended December 31, 2024 are preliminary and were prepared by the Company's management, based upon its estimates, a number of assumptions and current